Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment

Lancet Oncology

Volumn 6, Issue 3, 2005, Pages 158-166

  Toi, Masakazu ^a,b   Atiqur Rahman, Mohammad ^a   Bando, Hiroko ^a,b   Chow, Louis W C ^b,c  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b UNIMED Medical Institute and Organization for Oncology and Translational Research   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 6 [1 (2 IMINOPYRROLIDINYL)METHYL]URACIL; 5' O TRITYLINOSINE; 6 AMINO 5 CHLOROURACIL; 7 DEAZAXANTHINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; KIN 59; METHOTREXATE; MITOCHONDRIAL DNA; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; TAS 102; TEGAFUR; THYMIDINE PHOSPHORYLASE; TRIFLURIDINE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UFT; UNCLASSIFIED DRUG; URACIL;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; GENE EXPRESSION; HUMAN; METASTASIS; MOLECULAR MECHANICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION;

APOPTOSIS; DRUG DELIVERY SYSTEMS; FORECASTING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THYMIDINE PHOSPHORYLASE; UP-REGULATION;

EID: 14644393663     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)01766-3     Document Type: Review

References (92)

1. Miyazono K Okabe T Urabe A et al. Purification and properties of an endothelial cell growth factor from human platelets J Biol Chem 262 1987 4098-103
2. Ishikawa F Miyazono K Hellmann U et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor Nature 338 1989 557-62
3. Haraguchi M Miyadera K Uemura K et al. Angiogenic activity of enzymes Nature 368 1994 198
4. Zhang HT Craft P Scott PA et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells J Natl Cancer Inst 87 1995 213-19
5. Miwa M Ura M Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1998 1274-81
6. Nishigaki Y Marti R Copeland WC et al. Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency J Clin Invest 111 2003 1913-21
7. Ueda M Ueki K Kumagai K et al. Apoptosis and tumor angiogenesis in cervical cancer after preoperative chemotherapy Cancer Res 58 1998 2343-46
8. Koukourakis MI Giatromanolaki A O'Byrne KJ et al. bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer Clin Exp Metastasis 17 1999 545-54
9. Matsuura T Kuratate I Teramachi K et al. Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas Cancer Res 59 1999 5037-40
10. Kitazono M Takebayashi Y Ishitsuka K et al. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase Biochem Biophys Res Commun 253 1998 797-803
11. Ikeda R Furukawa T Kitazono M et al. Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose Biochem Biophys Res Commun 291 2002 806-12
12. Ikeda R Furukawa T Mitsuo R et al. Thymidine phosphorylase inhibits apoptosis induced by cisplatin Biochem Biophys Res Commun 301 2003 358-63
13. Sawada N Ishikawa T Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenograft Clin Cancer Res 4 1998 1013-19
14. Endo M Shinbori N Fukase Y et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models Int J Cancer 83 1999 127-34
15. Cassidy J Tabernero J Twelves C et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer J Clin Oncol 22 2004 2084-91
16. Sawada N Ishikawa T Sekiguchi F et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts Clin Cancer Res 5 1999 2948-53
17. Eda H Fujimoto K Watanabe S et al. Cytokines induce thymidine phophorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine Cancer Chemother Pharmacol 32 1993 333-38
18. Goto H Kohno K Sone S et al. Interferon gamma-dependent induction of thymidine phosphorylase/platelet-derived endothelial growth factor through gamma-activated sequence-like element in human macrophages Cancer Res 61 2001 469-73
19. Fukushima M Okabe H Takechi T et al. Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity Cancer Lett 187 2002 103-10
20. Zhu GH Schwartz EL. Expression of the angiogenic factor thymidine phosphorylase in THP-1 monocytes: Induction by autocrine tumor necrosis factor-α and inhibition by aspirin Mol Pharmacol 64 2003 1251-58
21. Griffiths L Dachs GU Bicknell R et al. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo Cancer Res 15 1997 570-72
22. Relf M LeJeune S Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis Cancer Res 57 1997 963-69
23. Matsumura M Chiba Y Lu C et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer Cancer Lett 128 1998 55-63
24. O'Byrne KJ Koukourakis MI Giatromanolaki A et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer Br J Cancer 82 2000 1427-32
25. Sivridis E Giatromanolaki A Gatter KC et al. Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma Cancer 95 2002 1055-1063
26. Currie MJ Gunningham SP Han C et al. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling Clin Cancer Res 7 2001 918-27
27. Usuki K Gonez LJ Wernstedt C et al. Structural properties of 3·0 kb and 3·2 kb transcripts encoding platelet-derived endothelial cell growth factor/thymidine phosphorylase in A431 cells Biochim Biophys Acta 1222 1994 411-14
28. Zhu GH Lenzi M Schwartz EL. The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells Oncogene 21 2002 8477-85
29. Jones A Fujiyama C Turner K et al. Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion J Urol 167 2002 1482-86
30. 3 J Biol Chem 278 2003 19272-79
31. Seeliger H Guba M Koehl GE et al. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy Clin Cancer Res 10 2004 1843-52
32. Evrard A Cuq P Robert B et al. Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: In vitro and in vivo study Int J Cancer 80 1999 465-70
33. Ciccolini J Peillard L Evrard A et al. Enhanced antitumor activity of 5-fluorouracil in combination with 2′-deoxyinosine in human colorectal cell lines and human colon tumor xenografts Clin Cancer Res 6 2000 1529-35
34. Kim R Murakami S Toge T. Effects of introduction of dThdPase cDNA on sensitivity to 5′-deoxy-5-fluorouridine and tumor angiogenesis Int J Oncol 22 2003 835-41
35. Toi M Ueno T Matsumoto H et al. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer Clin Cancer Res 5 1999 1131-37
36. Yao Y Kubota T Sato K et al. Macrophage infiltration-associated thymidine phosphorylase expression correlates with increased microvessel density and poor prognosis in astrocytic tumors Clin Cancer Res 7 2001 4021-26
37. Seki N Kodama J Hongo A et al. Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in endometrial cancer Int J Oncol 15 1999 781-86
38. Saji H Koike M Yamori T et al. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma Cancer 92 2001 1085-91
39. Toi M Gion M Saji H et al. Endogenous interleukin-12: Relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma Int J Oncol 15 1999 1169-75
40. Yamamoto Y Yamashita J Toi M et al. Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues Oncol Rep 10 2003 791-96
41. Koide N Nishio A Sato T et al. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus Am J Gastroenterol 99 2004 1667-74
42. Brown NS Jones A Fujiyama C et al. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors Cancer Res 60 2000 6298-02
43. Mori S Takao S Ikeda R et al. Thymidine phosphorylase suppresses Fas-induced apoptotic signal transduction independent of its enzymatic activity Biochem Biophys Res Commun 295 2002 300-05
44. Fang J Akaike T Maeda H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment Apoptosis 9 2004 27-35
45. Toi M Bando H Horiguchi S et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer Br J Cancer 90 2004 2338-43
46. Schwartz EL Baptiste N O'Connor CJ et al. Potentiation of the antitumor activity of 5-fluorouracil in color carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase Cancer Res 54 1994 1472-78
47. Morita T Matsuzaki A Tokue A. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA Int J Cancer 92 2001 451-56
48. Yamamoto Y Toi M Tominaga T. Prediction of the effect of 5′ deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients Oncol Rep 3 1996 863-65
49. Hata Y Takahashi H Sasaki F et al. Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5′-deoxy-5-fluorouridine (59DFUR) on breast cancer Breast Cancer 7 2000 37-41
50. Gasparini G Toi M Miceli R et al. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy Cancer J Sci Am 5 1999 101-11
51. Tominaga T Toi M Ohashi Y et al. Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients Clin Breast Cancer 3 2002 55-64
52. Yang Q Barbareschi M Mori I et al. Prognostic value of thymidine phosphorylase expression in breast carcinoma Int J Cancer 97 2002 512-17
53. Li H Suo Z Zhang Y et al. The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas Histol Histopathol 19 2004 129-36
54. Salonga D Danenberg KD Johnson M et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidne dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin Cancer Res 6 2000 1322-27
55. Nishimura G Terada I Kobayashi T et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy Oncol Rep 9 2002 479-82
56. Koizumi W Saigenji K Nakamaru N et al. Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor Oncology 56 1999 215-22
57. Kikuyama S Inada T Shimizu K et al. p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer Anticancer Res 21 2001 2149-53
58. Terashima M Fujiwara H Takagane A et al. Role of thymidine phosphorylase and dihydroprymidine dehydrogenase in tumour progression and sensitivity to doxofluridine in gastric cancer patients Eur J Cancer 38 2002 2375-81
59. Koizumi W, Hyodo J, Sakamoto J, et al. Response to capecitabine according to thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) expression profiles in gastric cancer (GC). Proc Am Soc Clin Oncol 2003; 22: 304 (abstr 1222).
60. Tahara M Ochiai A Fujimoto J et al. Expression of thymidine synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil Oncol Rep 11 2004 9-15
61. Saito H Tsujitani S Oka S et al. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma Br J Cancer 81 1999 484-89
62. Ishii R Takiguchi N Oda K et al. Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer Int J Oncol 19 2001 717-22
63. Noguchi T Fujiwara S Takeno S et al. Clinical impact of thymidine phosphorylase expression in gastric cancer Oncol Rep 10 2003 561-66
64. Nishina T Hyodo I Miyaike J et al. The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5′-deoxy-5-fluorouridine Eur J Cancer 40 2004 1566-71
65. Shimada H Hoshino T Okazumi S et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma Br J Cancer 86 2002 552-57
66. Hirano Y Takayama T Kageyama S et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between hisological parameters and chemosensitivity to 5-fluorouracil Eur Urol 43 2003 45-51
67. Talbot DC Moiseyenko V Belle SV et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracycline Br J Cancer 86 2002 1367-1372
68. Twelves C, Xeloda Colorectal Cancer Group. Capecitabine as first-line treatment in colorectal cancer: Pooled data from two large, phase III trials. Eur J Cancer 2002; 38 (suppl 2): S15-20.
69. Hong YS Song SY Lee SI et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer Ann Oncol 15 2004 1344-47
70. O'Shaughnessy J Miles D Vukelia S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results J Clin Oncol 20 2002 2812-23
71. Batista N Perez-Manga G Constenla M et al. Phase II study of capecitabine in combination with paclitaxel in patients with anthracyline-pretreated advanced/metastatic breast cancer Br J Cancer 90 2004 1740-46
72. Stuart N, Bishop JL, Johnson SRD, et al. Vinorelbine and capecitabine (VX) for advanced breast cancer - a phase II study showing good activity and potential for further development. Proc Am Soc Clin Oncol 2003; 2 46 (abstr 183).
73. O'Shaughnessy JA Blum J Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexete and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer Ann Oncol 12 2001 1247-54
74. Gradishar WJ Meza LA Amin B et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study J Clin Oncol 22 2004 2321-27
75. Ghosn M, Farhat F, Kattan J, et al. Final results of a phase II study of vinorelbine in combination with capecitabine as first line chemotherapy for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003; 22: 68 (abstr 270).
76. Patt YZ, Liebmann J, Diamandidis D, et al. Capecitabine plus irinotecan as first-line chemotherapy for metastatic colorectal cancer: Final findings from a phase II trial. Proc Am Soc Clin Oncol 2004; 23: 271 (abstr 3602).
77. Kim TW Kang YK Ahn JH et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer Ann Oncol 13 2002 1893-98
78. Park YH Ryoo BY Choi SJ et al. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer Br J Cancer 90 2004 1329-33
79. Bonnefoi H Biganzoli L Mauriac L et al. An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer Eur J Cancer 39 2003 1277-83
80. Rao S Cunningham D Price T et al. Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer Br J Cancer 91 2004 839-43
81. Dunst J Reese T Sutter T et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer J Clin Oncol 20 2002 3983-91
82. Livingston R. Current and planned trials with capecitabine in adjuvant/neoadjuvant therapy of breast cancer Oncology (Huntingtn) 16 suppl 12 2002 29-32
83. Akiyama S Furukawa T Sumizawa T et al. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression Cancer Sci 95 2004 851-57
84. Matsushita S Nitanda T Furukawa T et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors Cancer Res 59 1999 1911-16
85. Balzarini J Gamboa AE Esnouf R et al. 7-deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase FEBS Lett 438 1998 91-95
86. Liekens S Hernandez AI Ribatti D et al. The nucleoside derivative 5′-O-trityl-inosine (KIN59) suppresses thymidine phosphorylase-triggered angiogenesis via a noncompetitive mechanism of action J Biol Chem 279 2004 29598-605
87. Emura T Murakami Y Nakagawa F et al. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells Int J Mol Med 13 2004 545-49
88. Yano S Kazuno H Suzuki N et al. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: Discovery of novel orally active inhibitors of human thymidine phosphorylase Bioorg Med Chem 12 2004 3431-41
89. Franceschi F Genta RM Gasbarrini A et al. Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma Dig Liver Dis 34 2002 621-25
90. Nakajima Y Gotanda T Uchimiya H et al. Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose Cancer Res 64 2004 1794-801
91. Chung YL Troy H Judson IR et al. Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy Clin Cancer Res 10 2004 3863-70
92. Ueno T Toi M Saji H et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer Clin Cancer Res 6 2000 3282-89